A US biotechnology company has announced that it will begin testing coronavirus drugs in humans in Australia.
A US biotechnology company has announced that it will begin testing coronavirus drugs in humans in Australia. The company has said that the medicine will be ready by the end of this year.
According to Dr. Gregory Glenn, lead researcher of biotechnology company Novavax, the trial has begun on 131 people in Melbourne and Brisbane.
Coronavirus Glenn told an online press conference from NovaVax Maryland headquarters that they are working together to develop the drug and vaccine, which will be able to show that it works and will be available to the public by the end of the year.
Earlier, World Health Organization (WHO) Director General Tedros Adhanom had informed the United Nations Economic and Social Council (UNESC) that the corona vaccine was being developed rapidly and was estimated to be prepared before time.
"There are a total of 7 to 8 teams that are very close to developing this vaccine (Covid-19 Vaccine) and soon there will be big news for the world," Tedros said.
According to Tedros, many countries have reached out for help and about 100 different teams are testing the vaccine and eight of them are very close.
CoronavirusTwo months ago, he estimated that it would take 12 to 18 months to build, but work has progressed and it will develop ahead of time. However, Tedros has appealed to countries that they have raised about 8 billion dollars for research and development.
Once the vaccine is made, it will also require a large amount of production, so this amount is small.
Tedros said that he had recently appealed to 40 countries in this regard. Significantly, about a dozen experimental drugs in China, the United States and Europe are in the early stages of testing or are about to begin testing.
It is not yet clear whether any of these drugs will be safe and effective but many drugs work in different ways and are made with different techniques. This raises hopes that any of these drugs can be successful.
NovaVax said last month that they do not even touch the virus in their medicines, but in the end it looks like a virus for resistance. "It's the same way that NovaVax NanoPark makes a cold medicine," he said.
